Microgenomics in ameloblastoma by DeVilliers, Patricia
MICROGENOMICS IN AMELOBLASTOMA 
 
Patricia DeVilliers 
 
A thesis submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Master of Science in the 
Department of Dentistry. 
 
Chapel Hill 
 
2006 
 
Approved by 
 
Advisor: Dr. Tim Wright 
 
Reader: Dr. Valerie Murrah 
 
Reader: Dr. Bernard Weissman
ABSTRACT 
PATRICIA DEVILLIERS: Microgenomics in Ameloblastoma 
(Under the direction of Dr. Tim Wright) 
 Ameloblastoma, the second most common tumor arising from odontogenic 
epithelium of the jawbones, is characterized by a benign but locally invasive 
behavior with a high risk of recurrence. RNA was isolated and amplified from laser 
capture microdissected (AutoPix™) epithelial cells from five samples of formalin 
fixed decalcified paraffin embedded, (FFDPE) ameloblastoma tissue. The aminoallyl 
antisense RNA (aa-aRNA) was hybridized to 40,000-oligonucleotide expression 
microarrays and compared with Human Universal Reference RNA.  
Of the 210 significantly over-expressed genes, many were previously associated 
with tumor development, including Ras, cMic, Fos, WNT10A, FGF13 and T-cell 
acute lymphocytic leukemia 1. Other genes associated with tumor progression were 
also noted including Integrins, IL-17 , Spondin 2 and Beta adrenergic receptor 
kinase 2. Finally polymerase (DNA directed) gamma 2 , a DNA-repair gene 
product, was also up-regulated in ameloblastoma.  
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INTRODUCTION 
 
AMELOBLASTOMA 
Epidemiology 
 
Tumors arising from epithelium of the odontogenic apparatus or from its 
derivatives or remnants exhibit considerable histological variation. The World Health 
Organization classifies the odontogenic tumors into several benign and malignant 
entities as well as subtypes according to the presence or absence of odontogenic 
epithelium and odontogenic ectomesenchyme (Barnes et al., 2005). Ameloblastoma 
is the second most frequently encountered tumor arising from odontogenic 
epithelium of the jawbones, characterized by a benign but locally invasive behavior 
with a high risk of recurrence.  
 In 1995 a review evaluated of the biological profile of 3,677 cases of 
ameloblastoma from 1,500 journal articles including publications from 1960 to 1993 
in English, German, French, Italian, Portuguese, Korean and Japanese (Reichart, 
Philipsen, & Sonner, 1995). The findings were compared with reviews published by 
Waldron (Waldron, 1966), (Waldron & el-Mofty, 1987a). The median age in 
ameloblastoma is 35 years, with a range of 4-92 years. The tumor occurs mainly in 
younger patients in developing countries. Men and women are equally affected (47%
2females and 53% males). While cases have been reported from almost all parts of 
the world, a higher number of cases occur in Japan, Nigeria and U.S.A. and fewer 
cases in Australia and South America. Ameloblastomas represent 6%-25% of oral 
tumors and the percentage in oral biopsies corresponds to 0.04% in Caucasian 
Americans, 0.3% in African Americans, 5.2% in Nigerians and 6.7% in Asians. In 
general, it represents only 0.02% - 0.7% of pathology biopsies.  
Clinical Features 
 The main clinical symptoms are painless swelling, delayed tooth eruption, 
ulceration, mobility and displacement of teeth. The ratio of ameloblastoma of the 
mandible to maxilla is 5 to 1. About 14% of cases develop in the maxillary sinus and 
5% in the nasal cavity. Ameloblastomas arise most frequently in the molar and 
ascending ramus areas of the mandible except in Africans, where it develops in the 
anterior region of the jaws. The mandibular tumors occur 12 years earlier than those 
of the maxilla, having an average size of 4.3 cm. In patients from developing 
countries, the mandibular tumors have an average size of 6.3 cm compared to those 
from industrialized countries with 4.2 cm. This may be explained by the difference in 
access to health care.  
Radiographic features 
There is an equal number of ameloblastomas that present either as multilocular 
radiolucent lesions with sharp cortication or as unilocular radiolucencies. Other 
frequent findings include the presence of an impacted tooth (mostly third molars), 
root resorption and undefined borderline. Bone cupping can be evident in peripheral 
ameloblastomas while faint radiopacities are apparent in the desmoplastic variant. 
3Etiology 
Ameloblastoma is thought to originate from sources that include residual tooth 
germ epithelium, epithelium of odontogenic cysts, stratified squamous epithelium 
and epithelium of the enamel organ (Vickers & Gorlin, 1970). Several authors 
describe possible pathogenic mechanisms (Dunsche, Babendererde, Luttges, & 
Springer, 2003; Mosqueda-Taylor et al., 1997; Reichart et al., 1995) that include 
nonspecific irritants such as extraction, caries, trauma, infection, inflammation, or 
tooth eruption, nutritional deficit disorders and viral pathogenesis. No evidence of 
HPV infection has been detected by morphological examination, 
immunohistochemistry, in situ hybridization and conventional polymerase chain 
reaction (Migaldi et al., 2005). 
Ameloblastomas according to the WHO classification 
 The World Health Organization classification of ameloblastomas includes four 
types: unicystic, solid/multicystic, extraosseous/peripheral and desmoplastic (Barnes 
et al., 2005).  Unicystic ameloblastoma was first described in 1977 by Robinson 
and Martinez (Robinson & Martinez, 1977). The radiographic appearance of 
unicystic ameloblastoma is that of a unilocular radiolucency. ContRast-enhanced 
MRI (CE-MRI) is useful in differentiating this lesion from keratinizing cystic 
odontogenic tumor and dentigerous cyst by the observation of low signal intensity on 
T1-weighted images, high signal intensity on T2-weighted images and relatively thick 
rim enhancement with/without small intraluminal nodules (Konouchi et al., 2006). 
Clinically, unicystic ameloblastoma occurs in young patients, before the 5th decade 
of life (average age of 26 years) (Li, Wu, Yu, & Yu, 2000) and may behave less 
4aggressively than multilocular lesions, especially if associated with an impacted 
tooth. Lesions may be treated conservatively (enucleation, curettage), whenever all 
areas of the cystic lumen are controllable intraoperatively, since it shows lower 
recurrence rates than multicystic ameloblastomas. 
 Conventional ameloblastoma (solid/multicystic type) occurs in the jaws, 
rarely involves the sinonasal cavities and shows a marked preference for the 
posterior region of the mandible; however, this tumor has a site predilection for the 
symphysis in African children (Reichart et al., 1995). Most patients present with a 
multilocular radiolucent lesion; while a higher proportion of multilocular lesions have 
root resorption when compared with unilocular lesions, there is a higher proportion of 
unilocular lesions containing an embedded tooth (Fregnani, Fillipi, Oliveira, Vargas, 
& Almeida, 2002). MRI features show low signal intensity on T1-weighted images, 
high signal intensity with/without multifocal and markedly high signal intensity 
corresponding to numerous small cysts on T2-weighted images, and have good 
enhancement on contRast-enhanced T1-weighted images (Konouchi et al., 2006). 
The histologic evaluation of these tumors is based on the cytologic criteria produced 
by Vickers and Gorlin (Vickers & Gorlin, 1970). Histologically, there are two basic 
patterns, follicular and plexiform, which carry no clinical relevance. (Barnes et al., 
2005). The treatment of choice is radical surgical resection, including bone and 
adjacent structures, and is indicated to avoid recurrence, particularly when the tumor 
has eroded the cortical plate and reached the soft tissues. Recurrence can be noted 
up to ten years after initial treatment, with most cases presenting within the first 5 
years (Keszler, Paparella, & Dominguez, 1996; Reichart et al., 1995). Recurrences 
5in grafts have been reported and may come from the proximal stump, from the 
adjacent soft tissues, or from intraoperative contamination (Martins & Favaro, 2004). 
 Desmoplastic ameloblastoma is most commonly found in the maxilla, in the 
anterior/premolar area of the jaws and does not show the typical radiographic 
features of ameloblastoma. Scattered radiopacities are observed within the 
radiolucent lesion and can be mistaken for a non-ameloblastomatous lesion or even 
osteosarcoma (Durmus, Kalayci, Ozturk, & Gunhan, 2003). Histologically, it has 
pronounced desmoplastic stroma with compressed tumor islands usually lacking a 
central zone of stellate reticulum (Waldron & el-Mofty, 1987b). Tumor islands often 
infiltrate into marrow spaces of surrounding bone and there is no capsule formation; 
recurrence is common but not higher than the other tumor types.  
 Peripheral ameloblastoma is found exclusively in the gingiva. Theories 
regarding the origin include development from the extraosseous epithelial remnants 
of dental lamina and its organ derivatives within the underlying connective tissue. It 
can also arise from the basal cell layer of the oral mucosa, which is believed to have 
odontogenic potential (Gurol & Burkes, 1995). Histologically, the peripheral 
ameloblastoma resembles the intraosseous form. Clinically it presents as a slow 
growing, asymptomatic sessile, broad, or pedunculated 1- to 2-cm lesion covered by 
normal mucosa, with a firm consistency, smooth surface, and pink color. Superficial 
bone resorption is occasionally associated with the lesion. The recommended 
treatment is wide excision down to the periosteum. Recurrence occurs infrequently 
(Gavalda, 2005).  
6Malignant ameloblastoma has recently been sub-classified into metastasizing 
ameloblastoma and ameloblastic carcinoma on the basis of metastatic spread and 
cytologic malignant features (Barnes et al., 2005). Ameloblastic carcinoma refers to 
any ameloblastoma having histological evidence of malignancy in the primary tumor 
or the recurrent tumor, regardless of whether it has metastasized (Verneuil, Sapp, 
Huang, & Abemayor, 2002). The term malignant ameloblastoma is reserved for 
those metastasizing tumors that retain the typical morphology of ameloblastoma, are 
locally aggressive and have a high recurrence rate of 50–72%. The lungs are the 
most frequent site of metastases, followed by regional lymph nodes, pleura, 
vertebrae, skull, diaphragm, liver and the parotid glands. There is one report of 
bilateral renal metastasis in a patient, where the metastatic lesions showed 
histologically malignant transformation, even though all primary lesions had benign 
features (Hayakawa et al., 2004). Genetically, aneuploidy is more common in 
ameloblastic carcinomas than ameloblastomas and may be predictive of the 
malignant potential (Muller, DeRose, & Cohen, 1993). 
Genetics in Ameloblastoma 
 Immunoprofiling of ameloblastoma has been the topic of numerous papers in 
the past years. Expression of cytochrome c, APAF-1, caspase-9, and AIF in tooth 
germs and ameloblastomas suggests that the mitochondria-mediated apoptotic 
pathway has a role in apoptotic cell death of normal and neoplastic odontogenic 
epithelium. Expression of these mitochondrial apoptosis signaling molecules could 
be involved in oncogenesis, cytodifferentiation, and malignant transformation of 
odontogenic epithelium (Kumamoto & Ooya, 2005).  There is a relatively high 
7frequency of allelic loss in ameloblastic tumors. In order to identify mutational 
damage in tumor suppressor genes in microdissected samples of ameloblastomas 
and ameloblastic carcinomas, a panel of polymorphic microsatellite fluorescent-
labeled markers/primers was used for multiple suppressor genes on chromosomes 
1p, 3p, 9p,10q, and 17p (L-myc, hOGG1, p16, pten, and p53). Analysis of the tumor 
PCR products showed the highest frequency of loss at L-myc and pten. The 
frequencies varied somewhat between different tumor types but were not 
significantly different between the carcinomas and the benign tumors. Therefore, 
testing for allelic loss is not expected to provide clinical prognostic information (Nodit 
et al., 2004). 
 Chromosomal imbalances in ameloblastomas appear to be rare with losses in 
chromosomes 22 and 10 being the most frequently described (Jaaskelainen et al., 
2002). Deregulation of several genes in normal tooth development could play a role 
in the histogenesis of ameloblastoma. The cloning and characterization of 
expression of the ameloblastin (AMBN) and amelogenin genes in these tumors 
supports the hypothesis that ameloblastomas arise from the dental lamina, the outer 
enamel epithelium or the inner enamel epithelium (Kumamoto, Yoshida, & Ooya, 
2001). The undifferentiated phenotype of neoplastic cells could result from a direct 
action of AMBN in the target tissue or an indirect effect due to reciprocal signaling 
between the epithelial and mesenchymal components (Perdigao, Gomez, Pimenta, 
& De Marco, 2004). 
 Gene expression alterations were identified for the first time in six odontogenic 
tumors by the use of cDNA microarrays containing 19,000 human cDNAs. (Carinci et 
8al., 2003). Statistical analysis identified 506 genes associated with the tumors. 43 
cDNAs differentiated the three malignant odontogenic tumors (ameloblastic 
carcinoma, clear cell odontogenic tumor and granular cell odontogenic tumor) from 
the three benign ameloblastoma biopsies.  
 Gene expression profiling of ameloblastomas, using a commercial cDNA 
microarray with 588 cancer-related human cDNA fragments, has also been 
performed by using tooth germs as the reference tissue. Previous investigators 
showed that 34 genes had different levels of expression in the tumors compared 
with the tooth germs. FOS was the most highly over-expressed and 7 other genes 
such as Sonic Hedge Hog SHH and genes related to cell adhesion were under-
expressed in all tumors (Heikinheimo et al., 2002). Consequently, the possible role 
of SHH signaling molecules (SHH, PTC, SMO, GLI1) was studied in benign and 
malignant ameloblastoma, using RT-PCR and standard immunohistochemistry (IHC) 
with antibodies for the different SHH molecules. Results showed that mRNA 
transcripts were expressed in all the tumors and tooth germs, with no difference 
between benign and malignant tumors. Similar results were seen with the IHC levels 
where reactivity was found for all the SHH antibodies at somewhat variable degrees 
in different tissues. Therefore, SHH signal transduction seems to have a specific role 
in oncogenesis of odontogenic epithelium (Zhang et al., 2005). 
 Many other immunohistochemical studies have been reported in the literature 
as an attempt to understand the mechanism of development of ameloblastomas. 
Differences in p53 protein expression in different types of ameloblastomas have 
implicated tumor suppressor gene alteration as a potential oncogenic mechanism 
9(Toida et al., 2005). Apoptotic cell death in ameloblastomas (especially granular cell 
type) is increased, suggesting that apoptosis pathways also may be involved in 
tumorigenesis (Kumamoto & Ooya, 2005; Sandra, Hendarmin, Nakao, Nakamura, & 
Nakamura, 2005).  Parathyroid hormone-related protein (PTHrP) has been 
demonstrated in ameloblastoma and could play a significant role in local bone 
resorption, offering at least partial explanation for the tumor’s infiltrative growth and 
destructive behavior. The uniformity of PTHrP expression may have therapeutic 
implications, particularly through PTHrP-blocking treatment modalities (Abdelsayed, 
Vartanian, Smith, & Ibrahim, 2004). 
MICROGENOMICS 
 Since the sequencing of the human genome was completed, 
microgenomics is a powerful experimental approach, employing highly sophisticated, 
high-throughput platforms. However, these mainly chip-based methodologies can 
only generate biologically relevant data if the samples consist of homogenous cell 
populations, in which no unwanted cells of different specificity and/or developmental 
stage obscure the results. 
 Different methods have been routinely applied to overcome the problem 
presented by heterogeneous samples, e.g., global surveys, cell cultures and 
microdissection. Recently, laser-assisted microdissection methods have allowed for 
fast and precise procurement of extremely small samples. Through subsequent 
application of methods of linear mRNA amplification in a pool of isolated total RNA, it 
is now possible to perform high-throughput RNA expression profiling by 
microdissecting and processing even single-cell samples. Molecular profiling is now 
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increasingly important to the simultaneous study of many genes or proteins. Among 
the profiling platforms, the oligonucleotide array is applied to generate specific 
genetic fingerprints for individual lesions or distinct cell populations (Schena, Shalon, 
Davis, & Brown, 1995). 
 Originally, microdissection meant manually scraping off an area of interest from 
a sectioned tissue by the means of fine needles (Schena et al., 1998). The first 
laser-assisted microdissection method used selective ultraviolet radiation 
fractionation followed by polymerase chain reaction (PCR) to analyze specific cell 
subsets present on a microscope section (Shibata et al., 1992). A non-damaging, 
precise and fast method of laser-assisted cell selection was developed, the laser 
capture microdissection (LCM) process, at the National Institutes of Health (NIH) 
(Emmert-Buck et al., 1996). LCM selects the desired cells and tissue areas from a 
microscopic slide. The cells of interest are transferred onto a thin thermoplastic 
ethylene vinyl acetate film by pulsing of an infrared laser. The focally-softened film 
temporarily expands onto the targeted cell(s) and attaches to them. When the film, 
which is mounted to a plastic cap, is lifted off the microscopic sample slide, the 
tissue section shears at the edges of the tissue/polymer compound and the selected 
cells are removed along with the film and cap. Very small and highly complex 
structures can be easily microdissected by this method, including single cells (Luo et 
al., 1999). 
 Laser capture microdissection (LCM) can be used for molecular downstream 
analysis because the nucleic acids as well as the proteins are maintained intact and 
unaltered by the sampling process, as it does not generate any chemical bonds to 
11
the dissected cells (Webb, 2000). Furthermore, the RNA does not suffer any LCM-
derived impacts on quality, making it possible to use LCM to catalog the gene 
expression profiles of normal, precancerous, and malignant cells (Leethanakul et al., 
2000; Ohyama et al., 2000).  
 Laser-assisted microdissection is a fast way of precisely obtaining small 
samples or even single-cell samples, but the total RNA in such samples is usually 
too small for gene expression assays to be conducted. Expression profiling 
platforms typically require microgram quantities of RNA to be hybridized onto the 
arrays (Ohyama et al., 2002)(39). Luo et al. were the first to use LCM along with 
linear amplification of the isolated RNA (Luo et al., 1999). These two techniques 
together make it possible to generate, compare, and contRast gene expression 
profiles using only a small number of cells per sample. Numerous studies have been 
published, procuring small and homogenous samples, isolating the total RNA and 
amplifying its mRNA portion by linear T7-based protocols (Alevizos et al., 2001; 
Mohr et al., 2004; Naderi et al., 2004; Wu et al., 2005). This amplification method is 
now commonly known as the Eberwine protocol (Van Gelder et al., 1990). In a two-
step process, double-stranded cDNA is generated from mRNA while, 
simultaneously, a T7 promoter sequence is introduced. T7 polymerase is 
subsequently used to synthesize antisense-oriented RNA (aRNA) off this cDNA 
template, thereby amplifying the original template amounts up to 80-fold (Luo et al., 
1999; Ohyama et al., 2000; Ohyama et al., 2002). Currently, it is possible to amplify 
the original mRNA pool of a given sample up to 1,000,000-fold or even 10,000,000-
fold through two rounds of subsequent linear amplifications, without introducing bias 
12
into the samples. This allows working with as little as 10 intact cells or 50 
microdissected sectioned cells and still being able to generate enough aRNA for 
downstream array analysis.  
 (Coco et al., 2005; King et al., 2005; Mohr et al., 2004; Naderi et al., 2004).  
 Studies using the tools and methods of microgenomics have shed light on how 
those new approaches will eventually aid in the development of a new generation of 
diagnostics, e.g., leading to new patient-specific drugs tailored to the requirements 
assessed by assaying only a few biopsy cells (Taylor et al., 2004). In the present 
study we apply microgenomics to evaluate the gene expression profile of 
ameloblastomas. The goal of this study is to gain an understanding of the molecular 
mechanisms involved in initiating and maintaining tumorigenesis of this odontogenic 
tumor. 
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MICROGENOMICS IN AMELOBLASTOMA 
 
Background: Ameloblastoma, the second most common tumor arising from 
odontogenic epithelium of the jawbones, is characterized by a benign, but locally 
invasive, behavior with a high risk of recurrence. Microgenomics employs highly 
sophisticated, high-throughput platforms that can generate biologically relevant data 
if the samples investigated consist of homogenous cell populations. The purpose of 
this study was to carry out and analyze the gene expression profile of 
ameloblastoma using microgenomics. 
Methods: RNA was isolated from epithelial cells and amplified from five samples of 
formalin fixed decalcified paraffin embedded, (FFDPE) plexiform ameloblastoma 
tissue using laser capture microdissection (AutoPix™). The aminoallyl antisense 
RNA (aa-aRNA) was hybridized to 40,000-oligonucleotide expression microarrays 
and compared with Human Universal Reference RNA.  
Results: Of the 210 significantly over-expressed genes, many were previously 
associated with tumor development, including Ras, cMic, Fos, WNT10A, FGF13 and 
T-cell acute lymphocytic leukemia 1. Other genes associated with tumor progression 
were also noted including Integrins, IL-17, Spondin 2 and Beta, adrenergic, receptor 
kinase 2. Finally polymerase (DNA directed), gamma 2, a DNA-repair gene product, 
was also up-regulated in ameloblastoma. Studies using the tools and methods of 
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microgenomics of assessing only a few biopsy cells, combined with the analysis of 
tumorigenesis pathways will eventually aid in the development of a new generation 
of diagnostics and therapeutic tools in the management of ameloblastoma.  
Key terms: microgenomics; laser capture microdissection; ameloblastoma. 
 
INTRODUCTION 
 
Ameloblastoma is the second most frequently encountered tumor arising from 
odontogenic epithelium of the jawbones and is characterized by a benign but locally 
invasive behavior with a high risk of recurrence. Ameloblastomas are classified as 
solid/multicystic type, extraosseous/peripheral type, desmoplastic type and unicystic 
type (Barnes et al., 2005). Gene expression profiles were characterized for the first 
time in six odontogenic tumors using cDNA microarrays containing 19,000 human 
cDNAs. (Carinci et al., 2003). Statistical analysis identified 506 differentially 
expressed genes that were associated with the tumors. 43 cDNAs differentiated the 
three malignant odontogenic tumors (ameloblastic carcinoma, clear cell odontogenic 
tumor and granular cell odontogenic tumor) from the three benign ameloblastoma 
biopsies. Another gene expression profiling of ameloblastomas, using a commercial 
cDNA microarray target with 588 cancer-related human cDNA fragments, was 
performed by examining frozen tooth germs and ameloblastomas. A total of 34 
genes expressed levels in the tumors that were different from the tooth germs. FOS 
was the most highly over-expressed and 7 other genes such as SHH and genes 
related to cell adhesion were under-expressed in all tumors (Heikinheimo et al., 
2002). Consequently, a possible role of SHH signaling molecules (SHH, PTC, SMO,
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GLI1) was investigated in benign and malignant ameloblastoma suggesting that the  
expression of SHH, PTC and SMO, might play a role in epithelial-mesenchymal 
interactions and cell proliferation not only in normal tooth development as well as in 
tumorigenesis of ameloblastoma (Kumamoto,H. 2004; Zhang,L. 2005). 
A major challenge that precludes the genetic analysis of tumor tissue has been 
the technical difficulty of collecting pure populations of specific cells directly from 
complex heterogeneous tissue. Laser capture microdissection (LCM) is a technique 
that allows the isolation of individual cell populations for genetic analysis, thereby 
circumventing the impact of tissue heterogeneity. (Emmert-Buck et al., 1996; Webb, 
2000). Laser Capture microdissection (LCM) has proven to be an effective tool to 
isolate single cells with no detrimental effect on PCR amplification of DNA or RNA. 
LCM can be easily coupled with high density oligonucleotide array technology to 
obtain expression profiles from discrete cell populations in histologically complex 
tumors. Qualitative and quantitative assessment of isolated cellular RNA and 
inclusion of a set of internal transcript controls to monitor assay fidelity can greatly 
contribute to the success of this approach (Luzzi, Holtschlag, & Watson, 2001; Luzzi, 
Mahadevappa, Raja, Warrington, & Watson, 2003). 
The purpose of this study was to carry out and analyze the gene expression 
profile of the ameloblastoma basal cell layer using microgenomics with highly 
sophisticated, high-throughput platforms that can generate biologically relevant data 
if the samples investigated consist of homogenous cell populations. 
This study is the first to report the results of combining LCM and microarray 
gene expression profiling in formalin fixed decalcified paraffin embedded 
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ameloblastoma cells. Our results showed overexpression of Ras, cMic, Fos,
WNT10A, FGF13 and T-cell acute lymphocytic leukemia 1. Also, Integrins, IL-17, 
Spondin 2 and Beta adrenergic receptor kinase 2 were noted. 
MATERIALS AND METHODS 
Ameloblastoma samples 
 
This study was approved by the Institutional Review Board. The tissue samples 
were obtained from the paraffin block archives of the University of North Carolina 
Surgical Pathology Department that included the diagnosis of ameloblastoma. Five 
cases were selected based on the histological diagnosis following the criteria from 
the 2005 World Health Organization Histological Typing of Odontogenic Tumors.  
Formalin fixed paraffin embedded ameloblastoma tissue, dating back to 2004, 
had been previously decalcified in Richard Allan Scientifics’ Decalcifying Solution 
containing water, hydrochloric acid, ethylenediaminetetraacetic acid, tetra sodium 
tartrate, potassium sodium and tartrate. This decal solution offers rapid 
decalcification without destroying nuclear properties of the tissue. Glass slides for 
laser microdissection and microgenomics analysis were prepared from the formalin 
fixed, decalcified, paraffin embedded (FFDPE) tissue blocks  following the protocol 
from ParadigmArrayLabs™ and adapted from Arcturus Paradise Reagent System 
User Guide. RNase contamination from glass, work surfaces and equipment was 
removed using RNaseZap® Solution. Multiple sections, 7 µm thick, were cut from 
each sample block. The slides were air-dry for 30 minutes at room temperature. A 
total of 75 slides (15 from each ameloblastoma block sample) were prepared, RNA 
was extracted and amplified from the basal cell layer cells obtained by Laser 
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Capture Microdissection (LCM) using Arcturus’ AutoPix™ (Mountain View, CA), 
followed by labeling and hybridization of aa-aRNA for generation of gene expression 
profile. These steps were carried out by ParadigmArrayLabs™. 
Reverse Transcription - quantitative Polymerase Chain Reaction (RT-qPCR) 
from tissue scrapes: To test the fidelity of the RNA, five slides (one for each 
ameloblastoma sample) were stained with hematoxylin-eosin follow by tissue 
scraping and RNA extraction following the protocol of Optimum™ FFPE RNA 
Isolation Kit from Ambion, Inc. Austin, TX.  The RNA extracted from the tissue 
scrape samples was used to make complementary DNA (cDNA) via reverse 
transcription and Real Time- PCR was used to measure the RNA quality and 
quantity. In addition to the RNA samples, a control RNA was run to serve as 
template for a standard curve enabling quantitation of the sample material. Two 
primer sets were designed for beta-actin mRNA. The assessment protocol for the 
quality of RNA in FFPE tissue blocks measures the average beta-actin cDNA length 
by quantification of the PCR product yield from the 3’ end primer (primer 1107-1181) 
and another relative 5’ sequence (primer 697-773). The ratio of the RNA quantity 3’ 
and 5’ beta-actin Ct (threshold cycle) is an indicator of the quality of amplified RNA. 
A ratio value up to 10 indicates good RNA quality for microarray analyses and ratio 
value above 50 represent poorer quality RNA.  
Reverse Transcription equivalent score (RTE score): The RT score is a better 
predictor of the input amount for the RNA amplification reaction than the actual mass 
of the material. In parallel with the standard curve for the aRNA, the qPCR is 
performed for the diluted/non-diluted scraped sample. The 3’Ct values versus a 
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known amount of diluted/non-diluted scraped sample are plotted into a linear type 
chart. The 3’Ct value for 100pg uRNA, recorded from the standard curve, is plotted 
in the linear chart of the scrape sample and identifies the corresponding amount of 
the scrape sample.  
Laser capture microdissection (LCM): Once the quantity and quality of total 
RNA from the tissue scrapes were established, the cells from the basal layer of the 
ameloblastoma tissue in the five sample slides were cut using the  AutoPix™ laser 
capture microdissection system with an infrared diode laser (Arcturus Engineering, 
Santa Clara, CA, USA). The AutoPix™ LCM is an automated platform for high-
throughput microdissection of individual cells or multi-cellular structures from tissue 
sections. The process preserves spatial and cellular integrity throughout and 
enables accurate quality control of the cells selected for downstream analysis. A 
decision was made to microdissect the cells from the basal cell layer of the 
ameloblastoma rather than the stellate-like reticulum area to establish a baseline 
and to avoid the variability that metaplastic changes can confer to the stellate-like 
reticulum. In order to correctly identify the cells to be microdissected, H&E sections 
of the samples were scanned using the ScannScope™ system, at a magnification of 
40X. The scanned images were then viewed with the Aperio™ software. The tissue 
slides used for LCM were stained by ParadygmArrayLab™ with Hematoxylin and 
Eosin Stain. The samples were sealed in a completely enclosed environment during 
microdissection to minimize environmental effects and sample contamination. Each 
step of the microdissection process was documented with photographs. During the 
microdissection procedure, a CapSure™ cap was positioned over the tissue section 
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and at the end of the LCM the transparent thermoplastic film, which covers the cap, 
was peeled off and placed into the RNA extraction buffer. Total RNA was extracted 
from the microdissected cells following the protocol of Optimum™ FFPE RNA 
Isolation Kit from Ambion, Inc. Austin, TX. Before proceeding to the amplification, 
total RNA was quantified using the Nanodrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Inc., Montchanin, DE) and the quality assessed by the 
2100 electrophoresis bioanalyzer. (Agilent Technologies, Inc, Palo Alto, CA). 
RNA amplification: To generate antisense RNA (aRNA) by amplifying 
polyadenylated mRNA present in total RNA from the laser-captured samples, the 
TargetAmp™ 2-Round Aminoallyl-aRNA Amplification Kit from Epicentre® 
Biotechnologies was used. The protocol uses an improved “Eberwine”(Van Gelder et 
al., 1990) linear amplification process for amplifying Poly(A) RNA using the RTE 
score as an input for the total RNA. In parallel with the laser-captured samples, two 
other samples were included in the amplification: a positive control (human universal 
RNA) and a negative control (no RNA template). The TargetAmp 2-Round 
Aminoallyl-aRNA Amplification procedure protocol is briefly described as follows: 
1. First-strand cDNA Synthesis: The Poly (A) RNA component of a total RNA sample 
was reversed transcribed into first strand cDNA. The reaction was primed from a 
synthetic oligo (dT) primer containing a phage T7 RNA Polymerase promoter 
sequence at its 5’-end. First strand cDNA synthesis was catalyzed by SuperScript III 
Reverse Transcriptase and performed at an elevated temperature to reduce RNA 
secondary structure. 
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2. Second-strand cDNA Synthesis: The RNA component of the cDNA/RNA hybrid 
produced in Step 1 was digested into small RNA fragments using an RNase H 
enzyme and the primed to 2nd strand cDNA. The resulting product was a double-
stranded cDNA containing a T7 transcription promoter in an orientation that 
generated anti-sense RNA (aRNA) during the subsequent in vitro transcription 
reaction. The cDNA produced was used in the In Vitro transcription reaction without 
the need for purification. 
3. In vitro Transcription of Aminoallyl-aRNA: High yields of aminoallyl-aRNA were 
produced in a rapid in vitro transcription reaction that utilized the double-stranded 
cDNA produced in Step 2. In the transcription reaction, the canonical UTP nucleotide 
was partially substituted for with 5-(3-aminoallyl)-UTP aminoallyl-UTP; AA-UTP). 
Oligonucleotide Microarray Analysis: This study used the Whole Human Genome 
Oligo Microarray (G4112A) (Agilent Technologies Inc, Palo Alto, California). 60-mer 
oligonucleotides (double density format) probe sequences represent over 40,000 
human genes and transcripts on a 1“x 3” (25mm x 75mm) glass slide, enabling the 
whole-genome screening on a single microarray slide. Target labeling, hybridization, 
washing, scanning, and data extraction were performed following the 
Oligonucleotide Microarray Hybridization Protocol as previously described for the 
analysis of Eukaryotic RNA (Ohyama et al., 2000; Ohyama et al., 2002) 
In this project, RNA amplified from FFDPE samples was labeled with the Cy5 dye 
and hybridized to the Agilent™ array with a Cy3-labeled Stratagene Human 
Universal Reference sample (Novoradovskaya, Whitfield, Basehore, Novoradovsky, 
Pesich, Usary, Karaca, Wong, Aprelikova, Fero, Perou, Botstein, & Braman, 2004a). 
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The labeled cRNA from a single labeling reaction was used in all five hybridizations 
to minimize technical variance. 
Data analysis: The stained arrays were scanned at 488 nm using a G2500 
Scanner (Agilent, Palo Alto, CA). Statistical analysis of the microarray data was 
performed using Genespring™ software as well as Significance Analysis of 
Microarrays (SAM) (Larsson, Wahlestedt, & Timmons, 2005; Tusher, Tibshirani, & 
Chu, 2001). This statistical method interfaces with Microsoft Excel to determine if the 
expression of any genes is significantly related to the response variable.  
When testing the statistical significance for many genes, different methods of 
multiple testing corrections can be used to adjust the individual p-value to account 
for the effect of chance. In this study, we used the Benjamini and Hochberg false 
discovery rate, which is defined as the proportion of genes expected to occur by 
chance (assuming genes are independent) relative to the proportion of identified 
genes. There was no way to calculate this in advance, so the statement about the 
number expected will simply say that the expected number of genes by chance is 
100 % of the genes identified. This procedure provides a good balance between 
discovery of significant genes and protection against false positives. The occurrence 
of the latter is held to a small proportion of the list, and is probably a good choice of 
multiple-testing correction for most situations. 
RESULTS 
RNA, aRNA, and Array Quality: RNA assessment from tissue scrapes: The 
amount of total RNA yield from the tissue scrapes had a low 260/280 ratio, between 
1.39 and 1.74 (expected range 1.8 – 2.1) due to the degradation of RNA after 
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formalin fixation of the tissue. Values for the tissue scrape samples are included in 
the appendix under Table A1 as well as the standard curves for this experiment 
under Figure A1.  
Generation of gene expression profile using LCM: Laser capture 
microdissection used to isolate pure populations of basal cell layer ameloblastoma 
cells from formalin fixed decalcified paraffin embedded (FFDPE) samples yielded an 
estimated 500 cells and approximately 100-500 ng total RNA.  The values for the 
Total RNA characterization are included in the appendix under Table A2. 
The antisense RNA (aRNA) of 500 - 1,000 bp in length that was generated by two 
round amplifications showed a 260/280 ratio within an acceptable range. Anti-sense 
RNA generated from the ameloblastoma samples had an average size of 500 
nucleotides, indicating that good quality RNA was obtained reliably from LCM-
captured cells. The correlation between the phenotype of each sample, the 
histological presentation, the LCM extracted cells as well as the graphic 
representation of the aRNA is depicted in Table 1. All samples show similar 
histological pattern; the LCM cell follow the pattern of the basal cell layer, while the 
curve depicting the quality of the aRNA is consistent in all five samples. The 
characterization of the amynoallyl-antisense RNA (aa-aRNA) obtained from the 
samples is presented in Table A3 in the appendix. The yield of aminoallyl aRNA 
was, in all cases, sufficient to hybridize to the oligonucleotide array, which was 
performed following protocols previously described. (Luo et al., 1999)(Leethanakul et 
al., 2003). Oligonucleotide arrays have been reported as particularly attractive for 
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gene expression studies because they can readily distinguish expression levels of 
closely related gene family members. (King et al., 2005). 
Gene expression profile analysis: A normalization factor was estimated from 
ratios of the medians of the expression profiles. Normalization was performed by 
adding the log2 of the normalization factor to the log2 of the ratio of the medians. 
The log2 ratios for all the targets on the array were then calibrated using the 
normalization factor, and log2 ratios outside the 99.7% confidence interval were 
determined as significantly changed in the ameloblastoma samples. Scatter plots of 
the gene intensities of the samples are shown in Table A4 included in the appendix. 
Statistical analysis: Genespring® platform provided a comprehensive statistical 
analysis showing a total of 38 genes that were 2 fold up-regulated, all of which were 
present in all 5 samples. No down–regulated genes were filtered out at a significant 
P value. (Benjamini and Hochberg false discovery rate filter). This can be attributed 
to the stringency of the algorithm and to the fact that sample number 1 varied the 
most in its gene expression profile, when compared with samples 2, 3, 4 and 5. A 
possible explanation is that sample number 1 represented a case of recurrent 
ameloblastoma. Further studies would be useful to investigate the difference in 
genes expression between primary and recurrent ameloblastomas. Hierarchical 
clustering of the 5 arrays, 2-fold up and down-regulated genes is represented in 
Figure 1 and shows how samples 4 and 5 shared common gene expression; 
samples 2 and 3 have similar expression between them, while sample 1 is different 
to the other four samples and is the closest to the human uRNA reference (It may 
represent a different gene expression in a recurrent ameloblastoma). Table 2 shows 
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a partial list of 2-fold upregulated genes including annotations regarding their 
biological process, molecular function and pathways. 
The gene lists were also submitted to the Significance Analysis of Microarrays 
(SAM) which provides an estimate of False Discovery Rate for multiple testing. 
Table A5 in the appendix illustrates an example of SAM analysis for a dataset. A 
total of 10 up-regulated genes and 41 down-regulated genes, 2-fold, were present in 
all 5 samples. In order to make a comparison between the gene expression profile of 
the recurrent ameloblastoma sample and the other four samples, a separate 
analysis of samples 2, 3, 4 and 5 was also performed. It showed a total of 91 up-
regulated genes and 110 down-regulated genes, at a multiple of 2-fold. The different 
number of up and down-regulated genes obtained using  Benjamini and Hochberg 
false discovery rate filter as well as SAM is summarized in table 3. Among the 110 
down-regulated genes RAB31, member of the RAS oncogene family was noted as 
well as Interleukin 17 receptor; adrenergic, beta, receptor kinase 2 and suppression 
of tumorigenicity 13 (colon carcinoma). 
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Table 1. LCM samples and aRNA quality assessment. Ameloblastoma tissue sections (7 Vm) were 
stained with hematoxylin and eosin before performing LCM. The tissue prior to LCM (column 2), and 
the isolated tissue wedge after LCM (column 3),) is shown. For each sample, LCM was performed 
and the procured cells were pooled and RNA extracted and isolated. Column 4 shows the quality 
assessment graphs generated by the electrophoresis bioanalyzer, after each sample’s aRNA was 
amplified 
 
Sample Before LCM LCM aRNA 
Sample No.1 
51 year old Female 
Recurrent 
ameloblastoma. Left 
posterior mandible 
 
Sample No. 2 
27 year old female; left 
anterior mandible 
 
Sample No. 3 
14 year old Female 
posterior right 
mandible 
 
Sample No. 4 
34 year old  Female 
Left posterior maxilla 
 
Sample No.5 
17 years old Male 
Right posterior 
mandible 
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Figure 1. Hierarchical clustering of the 5 arrays, 2 fold up and down-regulated genes; samples 4 and 5 share 
common gene expression; samples 2 and 3 have similar expression between them. Sample 1 is different and the 
closest to the human uRNA reference (It may represent a different gene expression in a recurrent 
ameloblastoma) 
 
...
Selected Gene Tree: 2 fold 8877
Selected Condition Tree: 2 fold 8897
Colored by: 5arrays (Default Interpretation)
Gene List: 2_fold_up_down (8897)
2 fold...
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Table 2. Two-fold up-regulated genes present in all 5 ameloblastoma samples 
Common name Biological 
process* 
Molecular function* Pathways 
RAS-like, family 10, 
member B 
small GTPase mediated 
signal transduction 
GTP binding  
chromosome 21 open 
reading frame 70 
 
melanoma antigen family 
E, 1 
GO:4(biological process 
unknown) 
GO:5515(protein binding)  
MyoD family inhibitor cell differentiation; 
cytoplasmic sequestering 
of transcription factor; 
embryonic development 
receptor activity  
splicing factor, 
arginine/serine-rich 16 
(suppressor-of-white-
apricot homolog, 
Drosophila) 
nuclear mRNA splicing, 
via spliceosome 
 
wingless-type MMTV 
integration site family, 
member 10A 
development; frizzled-2 
signaling pathway 
signal transducer activity KEGG pathway: 
Hedgehog signaling 
pathway 04340; KEGG 
pathway: Wnt signaling 
pathway 04310 
acid phosphatase 5, 
tartrate resistant 
 acid phosphatase activity; 
hydrolase activity 
KEGG pathway: 
Riboflavin metabolism 
00740; KEGG pathway: 
gamma-
Hexachlorocyclohexane 
degradation 00361 
BTAF1 RNA polymerase 
II, B-TFIID transcription  
negative regulation of 
transcription 
ATP binding; helicase activity; 
transcription factor activity 
 
MYC binding protein 2 protein ubiquitination ubiquitin-protein ligase activity; 
zinc ion binding 
 
sema domain, 
transmembrane domain 
(TM), and cytoplasmic  
 
domain, (semaphorin) 6A 
apoptosis; axon 
guidance; cell surface 
receptor linked signal 
transduction;  
 
cytoskeleton organization 
and biogenesis; 
development; 
neurogenesis 
protein binding; receptor activity KEGG pathway: Axon 
guidance 04360 
similar to zinc finger protein  nucleic acid binding; zinc ion 
binding 
 
zinc finger protein 265 RNA splicing RNA binding; transcription factor 
activity 
 
leucine-rich repeat-
containing G protein-
coupled receptor 4 
G-protein coupled 
receptor protein signaling 
pathway 
protein-hormone receptor activity  
tenascin XB cell-matrix adhesion protein binding KEGG pathway: ECM-
receptor interaction 
04512; KEGG pathway: 
Focal adhesion 04510 
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Common name Biological 
process* 
Molecular function* Pathways 
symplekin cell adhesion protein binding KEGG pathway: Tight 
junction 04530 
colipase, pancreatic digestion; lipid catabolism enzyme activator activity  
casein alpha s2-like A transport transporter activity  
dual specificity 
phosphatase 9 
JNK cascade; inactivation 
of MAPK; protein amino 
acid dephosphorylation 
MAP kinase phosphatase 
activity; hydrolase activity 
KEGG pathway: MAPK 
signaling pathway 04010 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide 
N-
acetylgalactosaminyltransf
eRase 10 (GalNAc-T10) 
 manganese ion binding; 
polypeptide N-
acetylgalactosaminyltransfeRase
activity; sugar binding; 
transfeRase activity, transferring 
glycosyl groups 
KEGG pathway: O-
Glycan biosynthesis 
00512 
zinc finger, CW type with 
coiled-coil domain 3 
 ATP binding  
OTU domain, ubiquitin 
aldehyde binding 1 
GO:6955(immune 
response); 
GO:6512(ubiquitin cycle) 
GO:8234(cysteine-type 
peptidase activity) 
KEGG pathway: Biotin 
metabolism 00780; 
KEGG pathway: Lysine 
degradation 00310 
*Gene Ontology 
 
Table 3. Benjamini and Hochberg FDR and SAM. Number of genes 2 fold over-expressed 
in 5/5 samples and in 4/4 samples (after removing sample #1) 
 
Samples Multiple Benjamini and Hochberg FDR 
P <0.05 
SAM 
5/5 2-fold up 38 10 
5/5 2-fold down 0 41 
4/4 2-fold up 255 91 
4/4 2-fold down 0 110 
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DISCUSSION 
Using a microgenomics approach we have identified multiple molecular 
pathways that are likely to be involved in tumorigenesis and development of 
odontogenic tumors. 
The oncogenes that were found to be involved in tumorigenesis and/or cell 
differentiation of ameloblastoma include Ras (RAB31), c-Myc and cFos which 
corroborate the work of Heikinheimo et. al. who reported over-expression of the Fos 
oncogene (Heikinheimo,K. 2002). RAB31, a member of the RAS oncogene family, 
plays a role in GTPase mediated signal transduction and has a molecular function in 
GTP binding. It has been suggested that these oncogenes play a role in 
tumorigenesis via deregulation of cell proliferation. 
DNA-repair genes are important during DNA replication. Polymerase (DNA 
directed), gamma 2 was up-regulated in ameloblastomas. This gene product 
participates in ATP binding, single-stranded DNA binding and zinc ion binding as 
part of the DNA polymerase pathway.  
There are several tumor-suppressor genes identified in the literature that are 
beleived to play a role in odontogenic tumors: retinoblastoma (RB), p53,
adenomatous polyposis coli (APC), WNT-1, and patched (PTC) genes are well 
known (Ohki,K. 2004;144 Kumamoto,H. 2005). In this study, wingless-type MMTV 
integration site family, member 10A (WNT10A) proto-oncogene was found to be 
significantly up-regulated in ameloblastoma. WNT10A has a similar function to 
WNT10B in oncogenesis and in several developmental processes including 
regulation of cell fate and patterning during embryogenesis. It plays a key role in 
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carcinogenesis through activation of WNT-beta-catenin-TCF signaling pathway. As a 
ligand for members of the frizzled family of seven transmembrane receptors, it 
participates in signal transduction activity as part of the Hedgehog signaling pathway 
(KEGG pathway 04340) and the Wnt signaling pathway (KEGG pathway 04310). 
These gene products have been suggested as regulators of tooth development 
(Zhang, B. 2006). Gene products involved in cell growth that were found to be up-
regulated in this study in ameloblastoma include T-cell acute lymphocytic leukemia 
1; suppression of tumorigenicity 13 (colon carcinoma) as well as Fibroblast growth 
factor 13. The latter gene participates in cell-cell signaling, neurogenesis and signal 
transduction as part of MAPK signaling pathway and regulation of actin cytoskeleton 
pathway.  
 There are several categories of gene products identified with tumor 
progression. Among the cell-matrix adhesion molecules, integrin and alpha V 
(vitronectin receptor, alpha polypeptide, antigen CD51), which are part of the ECM-
receptor interaction pathway, were over-expressed in ameloblastoma in this study.  
In the category of matrix-degrading proteinases, an over-expression of MMP-1,
MMP-2 and MMP-9 was evident; these products are known to degrade basement 
membrane components contributing to local tumor invasion. Spondin 2, an 
extracellular matrix protein involved in cell adhesion, development, immune 
response and protein binding was also up-regulated. 
Several signal transducers were down-regulated in the study samples, 
including ameloblastoma. Adrenergic, beta, receptor kinase 2, has molecular 
functions in ATP binding as well as G-protein coupled receptor kinase activity and 
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transferase activity. Interleukin 17 receptor is part of the cytokine-cytokine receptor 
interaction pathway; a gene product labeled “similar to Laminin receptor 1”, a 
structural constituent of ribosome was also down-regulated in ameloblastoma 
possibly affecting the receptor activity. A partial list of the most relevant up-regulated 
and down-regulated genes is presented in Table 4. This analysis is just the 
beginning of many future studies to continue the evaluation of the possible role of 
many other genes in the tumorigenesis of ameloblastoma.  Perhaps there is a gene 
that can be manipulated chemically in order to reduce the size of the tumor and to 
prevent high morbidity which will benefit those patients who do not have readily 
available access to health care. 
Table 4. Summary of gene products implicated in tumorigenesis and progression in 
ameloblastoma 
 
TUMORIGENESIS 
Oncogenes Ras, Myc, Fos,
Growth Factors T-cell acute lymphocytic leukemia 1 
Suppression of tumorigenicity 13 
Fibroblast growth factor 13 (FGF13)
Tumor suppressor genes Wingless-type MMTV 10A (WNT-10A)
TUMOR PROGRESSIONN 
cell-matrix adhesion molecules Integrin, Spondin 2, 
signal transducers Beta, adrenergic, receptor kinase 2 
Interleukin 17 
Similar to Laminin receptor 1 
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CONCLUSION 
This study is the first to report the results of combining laser capture 
micodissection and microarray gene expression profiling in formalin fixed decalcified 
paraffin embedded ameloblastoma. Studies such as this, using oligonucleotide array 
experiments from small sample aRNA specimens are likely to generate additional 
functionally important data in the future that reflects the biological differences among 
disease entities. Many of the genes that were over-expressed in the study are 
involved in the regulation of oncogenesis, cell adhesion and signal transduction. 
Ameloblastoma is an aggressive tumor with a significant recurrence rate and 
potentially devastating functional effects on the patient. Presently, surgery is the 
therapy of choice for most ameloblastomas. The results of this investigation are 
exiting in that they reveal the possibility of utilizing proteins and receptor-factors from 
gene expression profiles to enhance the results of surgery alone. This can result in 
substantially decreased morbidity for the patient. 
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 APPENDIX 
 
Table A1. Tissue scrapes Ameloblastoma samples:  total RNA characterization 
The lower 260/280 ratio (expected range 1.8 – 2.1) is due to degradation of RNA 
after formalin fixation of the tissue. The reverse transcription equivalent score (RTE) 
was established to obtain total RNA input required into an amplification process. 
This score is determined by using the 3’ beta-actin Ct (threshold cycle) value 
equivalent of 100pg human universal RNA (uRNA). 
 
Sample ID ng/ul 260/280 Total yield (ng) 3'/5' ratio RTE score 
19724-3 17.1 1.43 256.5 12.6 11.5 ng 
6705-4 34.2 1.39 513 14 14 ng 
4234-5 20.4 1.58 306 13.84 13 ng 
11729-7 67.6 1.74 1014 15.9 11.2 ng 
8593-8 31.5 1.49 472.5 13.69 17 ng 
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Total RNA characterization 
 
Sample ID 
 ng/ul 260/280 Yield (ng)
19724-3 
 
9.9 
 
1.45 
 
148.5 
 
6705-4 
 
29.7 
 
1.64 
 
445.5 
 
4234-5 
 
16 
 
1.66 
 
240 
 
11729-7 
 
36.4 
 
1.52 
 
546 
 
8593-8 
 
21.6 
 
1.65 
 
324 
 
Table A2. Laser capture microdissection (LCM). Characterization of the total 
RNA extracted from captured samples. 
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aa-aRNA characterization 
 
samples 
 
RNA input 
 ng/Fl 260/280 Total yield (ng) 
19724-3_aRNA 10 ng 1905.2 2.13 42867 
6705-4_aRNA 10 ng 2115.9 2.12 47607.75 
4234-5_aRNA 10 ng 2083.3 2.12 46874.25 
11729-7_aRNA 10 ng 1746.4 2.14 39294 
8593-8_aRNA 10 ng 1809.8 2.14 40720.5 
Positive control 100 pg 1982.7 2.07 44610.75 
Negative control 0 pg 31.8 1.88 715.5 
Table A3. RNA amplification. Total yield of aa-aRNA obtained from seven 
samples, including five LCM samples, positive control (uRNA) and a negative 
control (no template). 
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Log ratio-Log Intensity Plots 
19724-3 6705-4 4234-5 
11729-7 8593-8 
Table A4. Comparison of hybridization signal intensities. Blue indicates the 
mean scaled hybridization intensity. Read and green are probe-sets that 
change more than twofold between the samples being compared. Each y axis 
is the log intensity of the single sample indicated. Each x axis is the log mean 
intensity of all samples.
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Table A5. SAM analysis for a set of Delta (H). The false discovery rate (FDR) is 
defined as the percentage of falsely significant genes compared to the genes called 
significant. 
 
SAM Analysis for a set of Delta (Y)
del
ta p 0
Number 
falsely 
significant 
Number 
called 
significant 
FDR 
1 0.2 0.433 24623.52 32095 0.332
2 0.4 0.433 12430.98 23207 0.232
3 0.6 0.433 3733.86 12295 0.131
4 0.8 0.433 1415.09 7780 0.079
5 1.0 0.433 669.04 5562 0.052
6 1.2 0.433 334.88 4255 0.034
7 1.4 0.433 189.63 3319 0.025
8 1.6 0.433 114.08 2632 0.019
9 1.8 0.433 76.92 2154 0.015
10 2.0 0.433 50.41 1726 0.013
11 2.2 0.433 32.52 1404 0.010
12 2.4 0.433 24.84 1186 0.009
13 2.6 0.433 19.14 1000 0.008
14 2.8 0.433 15.49 842 0.008
15 3.0 0.433 13.10 704 0.008
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Figure A1 (A and B). Reverse Transcription - quantitative Polymerase Chain 
Reaction (RT-qPCR): standard curve for 3’beta actin (A) and 5’beta actin (B). 
Real Time- PCR was used to measure the RNA quality and quantity from tissue 
scrapes. In addition to the RNA samples, a control RNA was run to serve as 
template for a standard curve enabling quantitation of the sample material. Two 
primer sets were designed for beta-actin mRNA. The ratio of the RNA quantity 3’ 
and 5” beta-actin Ct (threshold cycle) is an indicator of the quality of RNA. Ratio 
value up to 10 indicates good RNA quality for microarray analyses and ratio value 
above 50 represent poorer quality RNA sample. 
 
A B
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Figure A2. Identification of genes with significant changes in expression, 
using SAM. Scatter plot of the observed relative difference d(i) versus the expected 
relative difference d(i). The solid line indicates the line for observed d(i)=expected 
d(i), where the observed relative difference is identical to the expected relative 
difference. The dotted lines are drawn at a distance of Y = 1.2 from the solid line. 
The cutoffs for 2-fold induction and repression are indicated by the dashed lines. 
The potentially significant genes are indicated by the circles 
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